In a €2.75 million cash transaction, MedReleaf (TSX:LEAF) has acquired MED Colombia, a company with cannabis cultivation and production licenses in Colombia, the company announced on Wednesday (July 25).

Through the acquisition, MedReleaf can now produce low-cost, high-quality raw materials to serve its global supply chain, along with Colombia’s domestic medical cannabis market. MED Colombia’s license repertoire includes the production of cannabis oil extracts and a library of cannabis genetics.

“As the legalization of medical cannabis continues to expand, we must ensure that our ability to cultivate cost effectively extends beyond Canada to supply our global operations,” CEO of MedReleaf Neil Closner said in a statement.

“Colombia has one of the best climates in the world for cannabis cultivation and excellent regulation to protect the rights of growers and operators. With the acquisition of MED Colombia we continue to execute on our international strategy and will be well positioned to scale our global production as our business continues to grow.”

Colombia legalized medical cannabis in 2015, while MED Colombia received its government license for THC cannabis cultivation, along with its derivatives, in 2017. MedReleaf has had a Colombian team operating in the country since 2017, and with this newest acquisition, can now accelerate plans to establish a licensed cultivation and extraction facility.

In April, MedReleaf announced that it had completed an acquisition agreement for 1 million square feet of existing greenhouse infrastructure on a 69 acre property in Exeter, Ontario, along with 95 acres of adjacent land, for $26 million. Set to be the company’s third Canadian facility, MedReleaf expects its first harvest in 2019’s first quarter.

As of market close on Wednesday, MedReleaf stocks were down 1.83 percent on the TSX to close at C$24.64. TipRanks analysis currently has a “Moderate Buy” ranking based off two analyst ratings  for the company’s shares with an average price target of C$34.

The most recent analyst ranking came in June, one from Noel Atkinson from Clarus, who reiterated his “Hold” position in the company, while Vivien Azer from Cowen & Co. reiterated her “Buy” position with a price target of C$34.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Olivia Da Silva, hold no direct investment interest in any company mentioned in this article.

Strong Innovation Pipeline Continues to Drive Market Share Growth
Broken Coast’s First Foray into Cannabis 2.0
Solei Introduces First Limited Release Vape on the Market
Solei, RIFF, Good Supply and B!NGO Expand Product Offerings

Aphria Inc. (” Aphria ” or the ” Company “) ( TSX: APHA and NASDAQ: APHA ), a leading global cannabis company inspiring and empowering the worldwide community to live their very best life, today announced the expansion of its 510 Vape offering across its award-winning adult-use brand portfolio.

Keep reading... Show less

Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”). If you wish to serve as lead plaintiff, you must move the Court before the December 1 2020 DEADLINE . A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

To join the class action, go to or call Sophie Zhang, Esq. toll-free at 800-991-3756 or email for information on the class action.

Keep reading... Show less

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf Solutions“, “OILS”, or the “Company”), Canada’s most innovative cannabis extractor, is pleased to provide the following commercial and intellectual property update:

Cannabis Extraction Agreement with White Label Producer

Keep reading... Show less


Khiron Life Sciences Corp. (“ Khiron ” or, the “ Company ”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, is pleased to announce that it has closed today its previously announced “bought deal” short form prospectus offering of units (“ Unit s ”), including the exercise in full of the over-allotment option (the “ Offering ”).

Keep reading... Show less

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Executive Chairman, is scheduled to speak on a panel at the Cowen 2020 Boston Cannabis Conference on Wednesday, December 2, 2020 at 9:20 a.m. EST.

For more information regarding the Cowen 2020 Boston Cannabis Conference please visit:

Keep reading... Show less